<DOC>
	<DOC>NCT02800746</DOC>
	<brief_summary>The objective of the present study is to determine the impact of preoperative IV-iron (ferric carboxy maltose) supplementation on postoperative hematocrit values and allogenic blood transfusion amount in patients undergoing elective prognathic surgery.</brief_summary>
	<brief_title>Intravenous Iron Iron in Prognathic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Patients with prognathism in undergoing elective prognathic surgery Patients provided a written informed consent. Patients with sferritin &lt; 300 mg/dl (male) or 200 mg/dl (female) Patients with preoperative Hematocrit &gt; 39% (male) and &gt; 36% 9female)serum hemoglobin &gt;13 g/dL (male) and &gt;12 g/dL (female) Patients with history of anaphylaxis, iron overload, active infection. Patients with endocrine disease Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, antifibrinolytic agents or recombinant human erythropoietin, or undergoing acute normovolemic hemodilution.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prognathic surgery</keyword>
</DOC>